Tag: oligonucleotide therapy market players

Discover trends, market shifts, and competitive outlooks for the oligonucleotide therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Anticipated CAGR of the Oligonucleotide Therapy Market, and What Factors Will Drive It?#_x000D_

Recent years have seen a swift expansion in the size of the oligonucleotide therapy market. The market, valued at $5.55 billion in 2024, is projected to increase to $6.18 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.4%. This growth in the market size during the historic period is attributable to factors including heightened investment in research and development efforts, the entry of pioneering therapies into the market, advancements in gene editing techniques, the discovery of early-stage therapeutics, and the introduction of rnai and antisense oligonucleotide._x000D_

_x000D_

The market for oligonucleotide therapy is projected to expand swiftly in the forthcoming years, escalating to $9.82 billion by 2029, with a compound annual growth rate (CAGR) of 12.3%. Factors contributing to the growth during the forecast period include investments in research and development, increased global market reach, expansion into new therapeutic areas, strategies for modifying diseases, and changes in regulations. Key trends during this period will feature personalized treatments, improvement in delivery systems, advancements in RNA interference (RNAI), innovations in antisense oligonucleotide, and the incorporation of gene editing techniques._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp_x000D_

_x000D_

#What Are the Core Growth Drivers Propelling the Oligonucleotide Therapy Market Forward?#_x000D_

The escalating number of cancer patients worldwide is expected to foster the expansion of the oligonucleotide therapy market in the upcoming years. As reported by the American Cancer Society in January 2022, an estimated 1.9 million new instances of cancer and 609,360 cancer-related fatalities, approximately 1,670 deaths daily, are predicted in the US alone. The most prevalent cancers globally include lung, prostate, bowel, and female breast cancer, making up 43 percent of all new cancer diagnoses worldwide. Thus, the increasing global cancer prevalence rates are projected to stimulate the oligonucleotide therapy market’s demand over the future years._x000D_

_x000D_

#What Segment Types Define the Oligonucleotide Therapy Market Structure?#_x000D_

The oligonucleotide therapy market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types_x000D_

2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User_x000D_

3) By End User: Hospitals, Research Institutes_x000D_

_x000D_

Subsegments:_x000D_

1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides_x000D_

2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers_x000D_

3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3398&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Oligonucleotide Therapy Market?#_x000D_

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Emerging Trends that Are Influencing theOligonucleotide Therapy Industry Evolution?#_x000D_

Players in the oligonucleotide therapy market are channeling resources into R&D to innovate and decrease the adverse effects of the therapy on patients. The modernized oligonucleotides being developed facilitate precision treatment, providing the ability to decipher and target any gene with bare minimum side effects. Moreover, they have been instrumental in addressing patient-specific sequences contributing to rare diseases. In the month of April 2023, Qalsody, an antisense oligonucleotide (ASO), received FDA approval for its use in treating patients suffering from amyotrophic lateral sclerosis (ALS) linked to a mutation in the superoxide dismutase 1 (SOD1) gene. This medication is designed to target SOD1 mRNA to minimize the production of SOD1 protein._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report_x000D_

_x000D_

#What Is the Definition of the Oligonucleotide Therapy Market?#_x000D_

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides’ most popular application (polymerase chain reaction)_x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3398_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the CAGR of the Oil Downstream Products Market Influence Its Overall Growth by 2034?

In the past few years, the oligonucleotide therapy market has witnessed rapid expansion. The market size is expected to surge from $5.55 billion in 2024 to $6.18 billion in 2025, registering a compound annual growth rate (CAGR) of 11.4%. The remarkable growth during the historic period can be traced back to an increase in research and development investments, the introduction of initial therapies to the market, advancements in gene editing methodologies, early therapeutic breakthroughs, and the inception of rnai and antisense oligonucleotide.

The market size for oligonucleotide therapy is forecasted to experience swift expansion in the forthcoming years. The market is predicted to reach $9.82 billion by 2029, with a compound annual growth rate (CAGR) of 12.3%. The amplification during the forecast duration is due to factors like investment in research and development, worldwide market dissemination, therapeutic field widening, strategies for altering disease, and alterations in regulations. Prominent trends during the forecast span encompass personalized treatments, progress in delivery systems, developments in RNA interference (RNAI), advancements in antisense oligonucleotide, and the integration of gene editing techniques.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Market?

The anticipated surge in cancer cases worldwide is predicted to bolster the expansion of the oligonucleotide therapy market in the forecasted period. As projected by the American Cancer Society in January 2022, the US is expected to witness roughly 1.9 million fresh cancer diagnoses and approximately 609,360 cancer-related fatalities, which equates to around 1,670 deaths per day. Lung, prostate, bowel, and female breast cancer are the four most prevalent cancer types globally, contributing to 43 percent of all new cancer diagnoses. Hence, the increasing global cancer prevalence rates are expected to stimulate the oligonucleotide therapy market’s demand in the approaching years.

Get Your Free Sample of the Global Oil Downstream Products Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

Who Are the Leading Companies Pioneering Change in the Oil Downstream Products Market?

Major companies operating in the oligonucleotide therapy market include:

• Pfizer Inc._x000D_

• Merck & Co. Inc._x000D_

• GlaxoSmithKline plc_x000D_

• Gilead Sciences Inc._x000D_

• BioNTech SE_x000D_

What Are the Most Significant Trends Transforming the Oil Downstream Products Market Today?

Investments are being made by the participants in the oligonucleotide therapy market towards exploring new techniques for restructuring the therapy to lower its adverse effects on patients. The novel oligonucleotides enable a precision medicine approach and can be crafted to target any gene with limited side effects. This further aids in targeting sequences specific to patients that trigger rare diseases. In April 2023, the FDA acknowledged the utility of Qalsody, an antisense oligonucleotide (ASO) meant for the treatment of patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody focuses on SOD1 mRNA to minimize the formation of SOD1 protein.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

What Are the Key Components of the Oil Downstream Products Market, and How Do Its Segments Perform?

The oligonucleotide therapy market covered in this report is segmented –

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types

2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User

3) By End User: Hospitals, Research Institutes

Subsegments:

1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides

2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers

3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

Which Regions Are Leading the Charge in Oil Downstream Products Market Development?

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Elements Shape the Definition of the Oil Downstream Products Market?

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides’ most popular application (polymerase chain reaction)

Browse Through More Similar Reports By The Business Research Company:

Flow Cytometry Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/flow-cytometry-global-market-report

Pharmaceutical API Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: